FIREFLY NEUROSCIENCE

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

14 Nov 2024 17:30:18 By Nasdaq GlobeNewswire

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

06 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

25 Oct 2024 16:10:00 By Nasdaq GlobeNewswire

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

16 Oct 2024 09:20:13 By Nasdaq GlobeNewswire

Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder

15 Oct 2024 09:00:01 By Nasdaq GlobeNewswire

Firefly Neuroscience to Participate in Upcoming October Investor Conferences

11 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis

20 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform

10 Sep 2024 09:00:01 By Nasdaq GlobeNewswire

Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors

05 Sep 2024 11:48:48 By Nasdaq GlobeNewswire

Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11

26 Aug 2024 09:00:00 By Nasdaq GlobeNewswire